stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use. *Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD We ...

I am an experienced Risk Management Business Analyst at a Systemic Greek Bank, with a strong background in finance and risk analysis. I hold an MSc in Applied Risk Management from the University of Athens and have completed the ACA Certificate Level. My expertise lies in financial analysis, risk management, data analysis using SQL, Python, and machine learning tools. I have worked in diverse roles, from assurance to financial analysis and trade operations, across leading firms like EY, PwC, Alpha Bank, and ...

KB Home (NYSE:KBH) shares are down 7.9% to trade at $57.81, despite the homebuilder delivering better-than-expected fiscal fourth-quarter earnings and revenue after yesterday's close. The pullback comes as the company continues to face challenging housing market conditions and delivered fewer homes throughout 2025.For the quarter, profits came in at $1.55, topping estimates of $1.92, while revenue of $1.69 billion also exceeded expectations of $1.65 billion. Shares are today gapping below familiar support a ...

This audio is auto-generated. Please let us know if you have feedback It’s been another week with far more retail news than there is time in the day. Below, we break down some things you may have missed during the week and what we’re still thinking about. From consumer spending forecasts to Playboy energy drinks, here’s our closeout for the week.What you may have missedLevi’s brings Target vet on boardLevi Strauss & Co. appointed Jeffrey Jones to its board, effective Jan. 21, the company said in a Tuesday ...

Generac Holdings Inc (NYSE:GNRC) stock was last seen up 2.3% at $140.11, after Wells Fargo upgraded the power generator to "overweight" from "equal weight," with a price-target hike to $195 from $186. The firm cited AI data center growth, seeing an opportune buying opportunity after the shares' recent slide. GNRC notched its fifth-straight daily loss yesterday, still down 13.1% since the start of this week. The stock fell below several long-term trendlines during the tumble, now underneath all moving averag ...

Tencent is using a Japanese cloud service to access Nvidia Blackwell chips that remain banned to Chinese customers. ...

ATLANTA, Dec. 19, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Coupang, Inc. (“Coupang” or the “Company”) (NYSE: CPNG). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Coupang’s business, operations, and prospects, including allegations that:  (1) Coupang had inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for ...

Core Viewpoint - Salarius Pharmaceuticals has adjourned its 2025 Annual Meeting of Stockholders to solicit additional votes due to insufficient quorum, with the meeting reconvened for December 31, 2025 [1][2]. Company Information - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatment options for cancer patients, with two drug candidates in its portfolio: seclidemstat and SP-3164 [9]. - Seclidemstat is being studied in a Phase 1/2 clinical trial for hematologic cancers at MD Anderson Cancer Center, targeting myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [9]. - SP-3164 is an oral small molecule protein degrader currently in the IND stage [9]. - The company has received financial support for its drug candidates from various organizations, including the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas [9]. Meeting Details - The required quorum for the Annual Meeting is 34% of outstanding shares, but only approximately 30% of shares were represented at the time of adjournment [2][3]. - Stockholders eligible to vote are encouraged to do so via the Internet or phone, with the record date for voting remaining October 24, 2025 [3][4]. - The reconvened meeting will be held virtually, allowing stockholders to participate online [2]. Subsidiary Information - Salarius' subsidiary, Decoy Therapeutics Inc., is a preclinical-stage biotechnology company utilizing machine learning and AI tools to develop peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [7]. - Decoy has secured financing from institutional investors and various funding programs, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [7].

Eurozone consumer sentiment unexpectedly weakened in December despite cooling inflation and economic resilience against tariffs, a monthly indicator showed. ...

Few brands have been more associated with the fast-fashion boom of the last two decades than Zara, the flagship apparel chain owned by Spanish clothing giant Inditex SA. It may surprise some consumers to learn, then, that Zara has in fact reduced its global footprint over the last few years since the pandemic. The brand's decline in physical storefronts has been moderate but meaningful, from a third-quarter peak of around 2,139 stores in 2019 to just under 1,800 stores five years later, according to earning ...